Last reviewed · How we verify
Matching placebo for selinexor
This is a matching placebo control used in clinical trials for selinexor, not an active drug.
At a glance
| Generic name | Matching placebo for selinexor |
|---|---|
| Sponsor | Karyopharm Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A matching placebo is an inert formulation designed to be indistinguishable from the active drug (selinexor) in appearance, taste, and administration route. It is used in randomized controlled trials to serve as a control arm and assess the true efficacy of selinexor by accounting for placebo effects. The actual mechanism of action belongs to selinexor, which is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1.
Approved indications
Common side effects
Key clinical trials
- Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (PHASE3)
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (PHASE2, PHASE3)
- Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO] (PHASE3)
- Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo for selinexor CI brief — competitive landscape report
- Matching placebo for selinexor updates RSS · CI watch RSS
- Karyopharm Therapeutics Inc portfolio CI